Galderma, Supernus Sue Impax Over Rosacea Treatment

Law360, New York (May 31, 2011, 1:10 PM EDT) -- Galderma Laboratories Inc. and Supernus Pharmaceuticals Inc. hit generic drug maker Impax Laboratories Inc. with a patent infringement suit Thursday in Delaware over Impax's bid for regulatory approval to market its own version of the rosacea treatment Oracea.

The plaintiffs argue that Impax's recent filing of an abbreviated new drug application with the U.S. Food and Drug Administration seeking to manufacture a generic version of 40 mg doxycycline delayed-release capsules for oral administration infringes a patent owned by Supernus and licensed by Galderma.

"Plaintiffs will be...
To view the full article, register now.